[Chemoendocrine therapy of gastric "scirrhous" carcinoma]

An oral chemoendocrine treatment using Tamoxifen and FT-207 for female patients with gastric scirrhous carcinoma was developed at the National Cancer Center. The dose was oral Tamoxifen 20 mg/day b.i.d. combined with FT-207, 600 mg/day t.i.d. Since the results of the pilot trial were promising, a double-blind clinical study was performed in the National Cancer Center Hospital. In patients with non-curative surgery, the group of Tamoxifen and FT-207 had longer survival than those who received only FT-207 (p = 0.084) by the Generalized Wilcoxon's analysis. To confirm these results, a controlled clinical study is being undertaken with patients of both sexes, of scirrhous and non-scirrhous types, and in all after non-curative surgery.